Medical

Ampio Pharmaceuticals has announced that the final results from the AP-014 Phase 1 trial of inhaled Ampion in COVID-19 patients demonstrated a greater reduction in all-cause mortality than was seen in the preliminary results. In March 2021, Ampio reported that preliminary data from the trial showed a 62% reduction in all-cause mortality. After all patients completed … [Read more...] about Ampio says trial of inhaled Ampion in COVID-19 patients demonstrates 78% reduction in all-cause mortality

Covis Pharma said that a Phase 3 trial of Alvesco ciclesonide MDI for the treatment of COVID-19 in 400 patients who have not been hospitalized failed to meet its primary endpoint, which was freedom from COVID-19 symptoms for 24 continuous hours by Day 30. The difference in time to alleviation of patients' COVID-19 symptoms was 70.6% for the ciclesonide MDI and 63.5% … [Read more...] about Phase 3 trial of ciclesonide MDI for the treatment of COVID-19 fails to meet primary endpoint

Nasus Pharma said that a bioequivalence study of its FMXIN001 dry powder intranasal naloxone demonstrated that FMXIN001 was absorbed significantly faster than Emergent BioSolutions' Narcan naloxone nasal spray, with an AUC 163% of the Narcan AUC after 4 minutes, and continued to demonstrate higher levels of naloxone in the blood through the first hour post dosing. The … [Read more...] about Nasus Pharma says BE study demonstrates its intranasal dry powder naloxone is absorbed faster than Narcan nasal spray

Intravacc has announced that a pre-clinical study of its intranasal outer membrane vesicle (OMV)-based recombinant spike protein (rSP) vaccine candidate against SARS-CoV-2 nose spray vaccine in hamsters and mice demonstrated complete protection. The company announced in June 2020 that it had partnered with Wageningen Bioveterinary Research and Utrecht University to … [Read more...] about Intravacc announces results of pre-clinical study of its intranasal COVID-19 vaccine candidate

According to Union Therapeutics, a Phase 1 study of its UNI911 niclosamide solution met its primary endpoint, demonstrating "a strong safety profile" for both inhaled and intranasal delivery; the company said that the PK results were also encouraging. Union is developing the formulation for the prevention of COVID-19 (UNI91103) and for the treatment of COVID-19 … [Read more...] about Phase 1 study of Union Therapeutics’ inhaled and intranasal niclosamide meets all endpoints

Neupharma, which is developing inhaled teicoplanin for the treatment of MRSA lung infections in CF patients in partnership with Rare Partners, has announced that a Phase 1 PK study of the formulation in cystic fibrosis patients demonstrated that the concentration of teicoplanin measured in the sputum 24 hours post-dose was dose dependent and exceeded the minimum … [Read more...] about Positive Phase 1 results for Neupharma’s inhaled teicoplanin in CF patients